Summary
The aim of this study was to examine the possible influence on survival of delays prior to presentation and/or treatment among women with breast cancer. Duration of symptoms prior to hospital referral was recorded for 2964 women who presented with any stage of breast cancer to Guy’s Hospital between 1975 and 1990. Median follow-up is 12.5 years. The impact of delay (defined as having symptoms for 12 or more weeks) on survival was measured from the date of diagnosis and from the date when the patient first noticed symptoms to control for lead-time bias. Thirty-two per cent (942/2964) of patients had symptoms for 12 or more weeks before their first hospital visit and 32% (302/942) of patients with delays of 12 or more weeks had locally advanced or metastatic disease, compared with only 10% (210/2022) of those with delays of less than 12 weeks (P< 0.0001). Survival measured both from the date of diagnosis (P< 0.001) and from the onset of the patient’s symptoms (P= 0.003) was worse among women with longer delays. Ten years after the onset of symptoms, survival was 52% for women with delays less than 12 weeks and 47% for those with longer delays. At 20 years the survival rates were 34% and 24% respectively. Furthermore, patients with delays of 12–26 weeks had significantly worse survival rates than those with delays of less than 12 weeks. Multivariate analyses indicated that the adverse impact of delay in presentation on survival was attributable to an association between longer delays and more advanced stage. However, within individual stages, longer delay had no adverse impact on survival. Analyses based on ‘total delay’ (i.e. the interval between a patient first noticing symptoms and starting treatment) yielded very similar results in terms of survival to those based on delay to first hospital visit (delay in presentation).
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Afzelius, P., Zedeler, K., Sommer, H., Mouridsen, H. T. & Blichert-Toft, M. (1994). Patient’s and doctor’s delay in primary breast cancer. Acta Oncol 33: 345–351.
Alderson, M., Hamlin, I. & Staunton, M. (1971). The relative significance of prognostic factors in breast cancer. Br J Cancer 25: 646–656.
Bloom, H. J. G. Richardson (1957). Histological grading and prognosis in breast cancer. Br J Cancer 11: 339–377.
Burgess, C. C., Ramirez, A. J., Richards, M. A. & Love, S. B. (1998). Who and what influences delayed presentation in breast cancer. Br J Cancer 77: 1343–1348.
Charlson, M. E. (1985). Delay in the treatment of carcinoma of the breast. Surg Gynecol Obstet 160: 393–399.
Dennis, C. R., Gardner, B. & Lim, B. (1975). Analysis of survival and recurrence vs patient and doctor delay in treatment of breast cancer. Cancer 35: 714–720.
Early Breast Cancer Trialists’ Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1–15, 71–85.
Elwood, J. M. & Moorehead, W. P. (1980). Delay in diagnosis and long-term survival in breast cancer. BMJ 280: 1291–1294.
Facione, N. C. (1993). Delay versus help seeking for breast cancer symptoms: a critical review of the literature on patient and provider delay. Soc Sci Med 12: 1521–1534.
Feldman, J. G., Saunders, M., Carter, A. C. & Gardner, B. (1983). The effects of patient delay and symptoms other than a lump on survival in breast cancer. Cancer 51: 1226–1229.
Fentiman, I. S., Howell, A., Hamed, H., Lee, S. M., Ranson, M., Wall, J., Chaudary, M. A., Ash, C. M., Gregory, W. M., Sellwood, R. A. & Rubens, R. D. (1994). A controlled trial of adjuvant tamoxifen with or without prednisolene in post menopausal women with operable breast cancer. Br J Cancer 70: 729–731.
Fisher, E. R., Redmond, C. & Fisher, B. (1977). A perspective concerning the relation of duration of symptoms to treatment failure in patients with breast cancer. Cancer 40: 3160–3167.
GIVIO (1986). Reducing diagnostic delay in breast cancer. Cancer 58(8): 1756–1761.
Hainsworth, P., Henderson, M. & Bennett, R. (1993). Delayed presentation in breast cancer: relationship to tumour stage and survival. Breast 2: 37–41.
Huguley, C. M., Brown, R. L., Greenberg, R. S. & Clark, W. S. (1988). Breast self-examination and survival from breast cancer. Cancer 62: 1389–1396.
Kern, K. A. (1994). Medicolegal analysis of the delayed diagnosis of cancer in 338 cases in the United States. Arch Surg 129: 397–404.
Machiavelli, M., Leone, B., Romero, A., Perez, J., Vallejo, C., Bianco, A., Rodriguez, R., Estevez, R., Reinaldo, C., Dansky, C., Alvarez, L., Xynos, F. & Rabinovich, M. (1989). Relation between delay and survival in 596 patients with breast cancer. Oncology 46: 78–82.
MacArthur, C. & Smith, A. (1981). Delay in breast cancer and the nature of presenting symptoms. Lancet 1: 601–603.
Neave, L. M., Mason, B. H. & Kay, R. G. (1990). Does delay in diagnosis of breast cancer affect survival? Breast Cancer Res Treat 15: 103–108.
Nolvadex Adjuvant Trial Organisation (1988). Controlled trial of tamoxifen as a single agent in the management of early breast cancer. Br J Cancer 57: 608–611.
Raabe, N. & Fossaa, S. (1996). Primary invasive breast cancer in Oslo 1980–1989: incidence and delay. Acta Oncologica 35: 9–15.
Rabinovich, M., Vallejo, C., Perez, J. E., Rodriguez, R., Cuevas, M. A., Machiavelli, M. R., Lacava, J. A., Leone, B. A., Romero, A. O., Mickiewicz, E., Chacon, R. D. & Estevez, R. A. (1993). Impact of delay to treatment upon survival in 1067 patients with breast cancer. Int J Oncol 2: 197–201.
Richards, M. A., O’Reilly, S. M., Howell, A., George, W. D., Fentiman, I. S., Chaudary, M. A., Crowther, D. & Rubens, R. D. (1990). Adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy’s/Manchester trial. J Clin Oncol 8: 2032–2039.
Richardson, J. L., Langholz, F., Bernstein, L., Burciaga, C., Danley, K. & Ross, R. K. (1992). Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year. Br J Cancer 65: 922–926.
Rossi, S., Cinini, C., Di Pietro, C., Lombardi, C. P., Crucitti, A., Bellantone, R. & Crucitti, F. (1990). Diagnostic delay in breast cancer: correlation with disease stage and prognosis. Tumori 76: 559–562.
Rubens, R. D., Armitage, P., Winter, P. J., Tong, D. & Hayward, J. L. (1977). Prognosis in inoperable stage 3 carcinoma of the breast. Eur J Cancer 13: 805–811.
Rubens, R. D., Saxton, S., Tong, D., Winter, P. J., Knight, R. K. & Hayward, J. L. (1980). Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer 16: 351–356.
Rubens, R. D., Hayward, J. L., Knight, R. K., Bulbrook, R. D., Fentiman, I. S., Chaudary, M., Howell, A., Bush, H., Crowther, D., Sellwood, R. A., George, W. D. & Howat, J. M. T. (1983). Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet 1: 839–843.
Rubens, R. D., Bartelink, H., Engelsman, E., Haywood, J. L., Rotmensz, N., Sylvester, R., Van der Scheuren, E., Papadiamantis, J., Vassilaros, S. D., Wildiers, J. & Winter, P. J. (1989). Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC breast cancer cooperative group trial (10792). Eur J Cancer Clin Oncol 25: 667–678.
Scottish Cancer Trials Breast Group, ICRF Breast Unit, Guy’s Hospital, London (1993). Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341: 1293–1298.
Sheridan, B., Fleming, J., Atkinson, L. & Scott, G. (1971). The effects of delay in treatment on survival rates in carcinoma of the breast. Med J Aust 1: 262–267.
van Dongen, J. A., Bartelink, H., Fentiman, I. S., Lerute, T., Miolet, S., Oldhuis, G., van der Scheuren, E., Silvester, R., Tong, D., Winter, J. & van Zijl, K. (1991). Randomised clinical trial to assess the value of breast conserving therapy (BCT) in Stage I and Stage II breast cancer. EORTC 10801. In Proceedings of the 5th EORTC Breast Cancer Working Conference, Leuven: p, 13
Vernon, S. W., Tilley, B. C., Neale, A. V. & Steinfeldt, L. (1985). Ethnicity, survival and delay in seeking treatment for symptoms of breast cancer. Cancer 55: 1563–1571.
Wallgren, A., Silfersward, C. & Edlund, G. (1976). Prognostic factors in mammary carcinoma. Acta Radiol 5: 1–16.
Wilkinson, G. S., Edgerton, F., Wallace, H. J., Reese, P., Patterson, J. & Priore, R. (1979). Delay, stage of disease and survival from breast cancer. J Chron Dis 32: 365–373.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Richards, M., Smith, P., Ramirez, A. et al. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer 79, 858–864 (1999). https://doi.org/10.1038/sj.bjc.6690137
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690137
Keywords
This article is cited by
-
Surgical Cancer Care in Safety-Net Hospitals: a Systematic Review
Journal of Gastrointestinal Surgery (2023)
-
Impact of an intervention on waiting times in the surgical pathway of women with breast cancer: a quasi-experimental study
Journal of Public Health (2023)
-
Time to surgery and survival in breast cancer
BMC Surgery (2022)
-
An appropriate treatment interval does not affect the prognosis of patients with breast Cancer
Holistic Integrative Oncology (2022)
-
Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer
Breast Cancer Research and Treatment (2022)